UroGen Pharma
URGN
150 hedge funds and large institutions have $545M invested in UroGen Pharma in 2025 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 45 increasing their positions, 41 reducing their positions, and 30 closing their positions.
152% more call options, than puts
Call options by funds: $35.4M | Put options by funds: $14.1M
37% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 30
18% more capital invested
Capital invested by funds: $460M → $545M (+$85M)
8% more funds holding
Funds holding: 139 → 150 (+11)
10% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 41
3.96% less ownership
Funds ownership: 90.27% → 86.32% (-4%)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$21M |
| 2 |
Morgan Stanley
New York
|
+$15.6M |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$13.8M |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$13.3M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$9.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$48.2M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$35.5M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$23.8M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$13M |
| 5 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
-$11M |
URGN Hedge Fund Activity: Q2 2025 in Review
150 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q2 2025, worth a combined $545M — up 18% from $460M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new URGN positions and 30 closed out — a net gain of 11 holders — while 45 added to existing stakes and 41 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $21M. The largest seller was UBS AM, exiting entirely with an estimated $48.2M sold.
- 150 institutional investors held UroGen Pharma (URGN) as of Q2 2025, up from 139 in Q1 2025.
- Funds reported $545M of UroGen Pharma stock for Q2 2025, up 18% quarter-over-quarter.
- 41 funds opened new UroGen Pharma positions in Q2 2025 and 30 closed out, a net change of +11 holders.
- The largest UroGen Pharma buyer in Q2 2025 was Soleus Capital Management, an estimated $21M added.
- The largest UroGen Pharma seller in Q2 2025 was UBS AM, an estimated $48.2M sold.
Based on aggregated 13F filings for Q2 2025.